Agricultural Bank Of China (601288.SH)'s application for issuing A-shares to specific targets has been accepted by the Shanghai Stock Exchange.
Agricultural Bank of China (601288.SH) announced that on October 8, 2026, the company received a notice issued by the Shanghai Stock Exchange (the "SSE") regarding the acceptance of the application by Agricultural Bank of China Limited, a company listed on the SSE Main Board, to issue securities. The SSE, in accordance with relevant regulations, reviewed the prospectus and related application documents submitted by the company for the issuance of securities by a company listed on the SSE Main Board, and determined that the application documents are complete and comply with statutory requirements. The SSE decided to accept the application and will conduct a review in accordance with the law.
Agricultural Bank Of China (601288.SH) announced that on October 8, 2026, the company received a notice from the Shanghai Stock Exchange (the "SSE") regarding the acceptance of the application for securities issuance by a company listed on the SSE Main Board, Agricultural Bank Of China Limited. The SSE, in accordance with relevant regulations, reviewed the prospectus and related application documents for securities issuance by the SSE Main Board-listed company submitted by the company, and determined that the application documents are complete and comply with statutory requirements. The SSE decided to accept the application and conduct review in accordance with the law.
Related Articles
Shenwan Hongyuan Group (06806): Zhang Xi nominated as candidate for non-executive director
Jiangsu Lopal Tech. Group (02465)'s second-tier controlling subsidiary, Nanjing Lihyuan, signed a Strategic Cooperation Framework Agreement with Jiyao Tongxing.
Lepu Medical Technology (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection.
Shenwan Hongyuan Group (06806): Zhang Xi nominated as candidate for non-executive director
Jiangsu Lopal Tech. Group (02465)'s second-tier controlling subsidiary, Nanjing Lihyuan, signed a Strategic Cooperation Framework Agreement with Jiyao Tongxing.
Lepu Medical Technology (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection.
